ClinicalTrials.gg
CompletedNCT01900431SARILNIUSATURNUpdated Jun 20, 2017Results posted

Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis

A Phase 2 interventional study of Sarilumab and Prednisone in Uveitis, sponsored by Sanofi. Completed at 20 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-20.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Uveitis with a site in Turkey — 2 open to participants now, 2 under way, none of them phase 3. Uveitis · Turkey.

Started
2013
the only one that year
Phase 2
Only one
of the 11
Registered
7th of 11
by date
Lead sponsor
1 of 11
Sanofi

Among the 11 studies in Uveitis with a site in Turkey, this one is the only one that started in 2013, is the only one in phase 2, and was the 7th registered.

Uveitis

300 studies on the registry are indexed under Uveitis; 33 are open to participants now.

Browse Uveitis studies →

Open to participants now

2 of the 11 studies in Uveitis with a site in Turkey are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 22 Uveitis studies recruiting now, 13 (59%) set no upper age limit and 9 (41%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Uveitis with a site in Turkey, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate the efficacy of sarilumab at Week 16 in participants with non-infectious uveitis (NIU).

Secondary Objectives:

To evaluate the change in best corrected visual acuity (BCVA). To evaluate the safety of subcutaneous sarilumab in participants with NIU. To evaluate the change in macular edema. To evaluate the change in other signs of ocular inflammation. To evaluate the effect on retinal vessel leakage. To evaluate the effect of sarilumab on reducing concomitant immunosuppressant therapy.

To evaluate the change in ocular inflammation in the anterior chamber. To evaluate the pharmacokinetics of sarilumab in NIU participants. To evaluate the immunogenicity with anti-drug antibodies (ADA).

Read the detailed description

The total duration per participant was up to 58 weeks, which included a 2 week screening period, 16 weeks principal treatment period (Part A), 34 weeks extension treatment period (Part B) or open label treatment period (Part C), and 6 weeks after last treatment administration.

Participants with decrease in vitreous haze (VH) ≥2; or corticosteroids dose \<10 mg/day at Week 16 were considered as responders. Participants who did not complete the principal treatment period (Part A) due to lack of efficacy; or no decrease in VH ≥2 and corticosteroids dose ≥10 mg/day at Week 16; or no decrease in VH ≥2 and corticosteroids dose missing at Week 16; or non-responder according to medical review, were considered as non-responders.

Responder participants, observed at Week 16 (at the end of Part A), were invited to continue in the extension treatment period (Part B).

Non-responder participants, observed within the first 16 weeks, were offered to be treated by open-label sarilumab (Part C).

03

Conditions studied

  • Uveitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years of age.
  • Non-infectious intermediate, posterior, or pan-uveitis in the study eye.
  • Active disease at screening or evidence of activity within the 3 months prior to screening visit. Following the approval of amendment-2, only participants with "active disease" as defined above were enrolled in the study.
  • Starting oral prednisone dose must be greater than or equal to 15 mg/day and less than 80 mg/day.
  • At screening, participants must be receiving oral prednisone (≥15 mg and \<80 mg/day [or equivalent oral ]) as single therapy or in combination with MTX (≤25 mg/week) orally or intravenously or intramuscular or subcutaneous). -
  • Participants could be receiving one or several of the following therapies: Azathioprine (≤2.5 mg/kg/day), Mycophenolate mofetil (≤2 g daily, orally), Cyclosporine (≤4 mg/kg daily, orally), Tacrolimus (≤4 mg daily, orally).
  • The doses might not had been increased for at least 4 weeks prior to the randomization visit.
  • At randomization, participants had been receiving oral prednisone (≥15 mg and \<80 mg/day [or equivalent oral corticosteroid]) as single immunosuppressive therapy or in combination with MTX (≤25 mg/week) orally or intravenously or intramuscular or subcutaneous).
  • Azathioprine, mycophenolate mofetil, cyclosporine and tacrolimus had to be permanently discontinued at least 48 hours prior to the first study treatment injection, or longer as per Investigator's judgment. These immunomodulatory therapies (IMTs) were not permitted anytime during the treatment period.
  • Signed written .

Exclusion criteria

Exclusion criteria:

  • Participants with best-corrected visual acuity (BCVA) worse than 20 early treatment diabetic retinopathy study (ETDRS) letters in at least one eye.
  • Participants with confirmed or suspected uveitis of infectious etiology or uveitis of traumatic etiology.
  • Participants with primary diagnosis of anterior uveitis.
  • Prior treatment with anti-interleukin-6 (IL-6) or interleukin-6 receptor complex (IL-6R) antagonist therapies, including tocilizumab and sarilumab.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
58 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo (for Sarilumab) subcutaneous (SC) injection every 2 weeks (q2w) for 16 weeks during principal treatment period (Part A) with background therapy of Prednisone (or equivalent oral corticosteroid) ≥15 mg/day and \<80 mg/day as single therapy or in combination with Methotrexate (MTX) 10 to 25 mg/week and folic acid per local prescribing practice. Responders continued with the same treatment regimen up to Week 50 during extension treatment period (Part B) and non-responders were proposed to be treated with open-label Sarilumab 200 mg q2w in open-label treatment period (Part-C).

    Drug: Sarilumab · Drug: Prednisone · Drug: Methotrexate · Drug: Folic/folinic acid · Other: Placebo (for Sarilumab)

  • Experimental
    Sarilumab 200 mg q2w

    Sarilumab 200 mg SC injection q2w for 16 weeks during principal treatment period (Part A) with background therapy of Prednisone (or equivalent oral corticosteroid) ≥15 mg/day and \<80 mg/day as single therapy or in combination with MTX 10 to 25 mg/week and folic acid per local prescribing practice. Responders continued with the same treatment regimen up to Week 50 during extension treatment period (Part B) and non-responders were proposed to be treated with open-label Sarilumab 200 mg q2w in open-label treatment period (Part-C).

    Drug: Sarilumab · Drug: Prednisone · Drug: Methotrexate · Drug: Folic/folinic acid

Interventions

  • Pharmaceutical form: Prefilled syringes; Route of administration: Subcutaneous

    Also known as: SAR153191/REGN88

  • Pharmaceutical form: Tablet or Capsule; Route of administration: Oral

  • Pharmaceutical form: Tablet or Capsule or Suspension; Route of administration: Orally or intravenously or intramuscular

  • DrugFolic/folinic acid

    Drug page: Leucovorin

    Pharmaceutical form: Tablet or Capsule; Route of administration: Oral

  • OtherPlacebo (for Sarilumab)

    Pharmaceutical form: Prefilled syringes; Route of administration: Subcutaneous

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With at Least 2-step Reduction in Vitreous Haze (VH) or Prednisone Dose <10 mg/Day at Week 16

    At least 2-step reduction in VH per central review from baseline was evaluated on Miami 9-step scale. VH is the obscuration of fundus by vitreous cells and protein exudation. Each of the 9-step scale (from grade 0 \[low opacity\] to 8 \[more opacity\]) images (in increasing order of opacity) are equivalent to approximately 0.3 log units of degradation in visual acuity based on the Bangerter calibration. Participants with prednisone dose \<10 mg/day (or equivalent oral corticosteroid) were also evaluated.

    Time frame: Week 16

Secondary outcomes

  1. Change From Baseline in VH Scale at Week 16

    Change from baseline in VH scale was evaluated on Miami 9-step scale. VH is the obscuration of fundus by vitreous cells and protein exudation. Each of the 9-step scale (from grade 0 \[low opacity\] to 8 \[more opacity\]) images (in increasing order of opacity) were equivalent to approximately 0.3 log units of degradation in visual acuity based on the Bangerter calibration. Least squares (LS) mean was calculated using mixed model for repeated measurements (MMRM) model with treatment groups, visits and visit-by-treatment groups interaction as fixed categorical effects as well as fixed continuous covariate of baseline adjudicated VH.

    Time frame: Baseline to Week 16

  2. Percentage of Participants With Anterior Chamber (AC) Cell Score = 0 or At Least 2-step Reduction in Score at Week 16

    Participants with AC cell score = 0 or with ≥2 step reduction from baseline at Week 16 were evaluated. Slit lamp examinations were conducted at each visit to assess AC cell count. The number of AC cells observed within a 1 mm × 1 mm slit beam was used to determine the grade according to the Standardization of Uveitis Nomenclature (SUN) criteria: grade 0 = no cells; grade +0.5 = 1 - 5 cells; grade +1 = 6 - 25 cells; grade +2= 26 - 50 cells; grade +3 = too many to count.

    Time frame: Week 16

  3. Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at Week 16

    BCVA score is based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters, and then at 1 meter. The range of ETDRS is 0 to 100 letters. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. LS mean was calculated using MMRM model with treatment groups, randomization strata of VH level (\<4, \>=4), visits and visit-by-treatment groups interaction as fixed categorical effects, as well as, fixed continuous covariate of baseline BCVA.

    Time frame: Baseline to Week 16

  4. Change From Baseline in Central Retinal Thickness (CRT) At Week 16

    CRT was measured by spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. All images were transmitted to the central reading center. SD-OCT was performed in the study eye after pupil dilation. LS mean was calculated using MMRM model with treatment groups, randomization strata of VH level (\<4, \>=4), visits and visit-by-treatment groups interaction as fixed categorical effects, as well as, fixed continuous covariate of baseline CRT.

    Time frame: Baseline to Week 16

  5. Percent Change From Baseline in CRT at Week 16

    CRT was measured by SD-OCT, a non-invasive diagnostic system providing high-resolution imaging sections of the retina. All images were transmitted to the central reading center. SD-OCT was performed in the study eye after pupil dilation. LS mean was calculated using MMRM model with treatment groups, randomization strata of VH level (\<4, \>=4), visits and visit-by-treatment groups interaction as fixed categorical effects, as well as, fixed continuous covariate of baseline CRT.

    Time frame: Baseline to Week 16

  6. Percentage of Participants With CRT Thickness <300 Microns at Week 16

    Time frame: Week 16

  7. Percentage of Participants Without Retinal Vessel Leakage on Fluorescein Angiography (FA) at Week 16

    Time frame: Week 16

  8. Percentage of Participants With Prednisone Dose of ≤5 mg/Day (or Equivalent Oral Corticosteroid) at Week 16

    Participants with prednisone dose ≤5 mg/day (or equivalent oral corticosteroid) at Week 16 were evaluated.

    Time frame: Week 16

  9. Pharmacokinetics (PK) Assessment: Serum Functional Sarilumab Concentration

    Serum functional (unbound) sarilumab concentrations were determined using an enzyme-linked immunosorbent assay (ELISA) method with a lower limit of quantification (LLOQ) of 294 ng/mL. Concentrations below LLOQ were set to zero for samples at predose. Post-treatment concentrations below LLOQ were replaced by LLOQ/2. The samples were considered non-eligible for the analysis if the previous dosing time was \<11 days or \>17 days before the sampling time for every other week regimens.

    Time frame: Predose on Day 1 (Baseline), Week 2, 4, 8, 12, 16, 24, 36, 52, and end of study (EOS) (Week 56)

07

Results

Posted Jun 20, 2017

Participant flow

The study was conducted at 18 centers in 6 countries. A total of 82 participants were screened between 30 October 2013 and 17 March 2015 of whom 58 participants were randomized and 24 were screen failures. Screen failures were mainly due to exclusion criteria met.

Principal Treatment Period (Part A)
Participant flow — Principal Treatment Period (Part A)
MilestonePlaceboSarilumab 200 mg q2wSarilumab 200 mg q2w (Open-Label Treatment)
Started20380
Completed13280
Not completed7100
Withdrew: Adverse event130
Withdrew: Lack of efficacy660
Withdrew: Other than specified above010
Extended Treatment Period (Part B)
Participant flow — Extended Treatment Period (Part B)
MilestonePlaceboSarilumab 200 mg q2wSarilumab 200 mg q2w (Open-Label Treatment)
Started8220
Completed7120
Not completed1100
Withdrew: Adverse event020
Withdrew: Lack of efficacy170
Withdrew: Other than specified above010
Open-Label Treatment Period (Part C)
Participant flow — Open-Label Treatment Period (Part C)
MilestonePlaceboSarilumab 200 mg q2wSarilumab 200 mg q2w (Open-Label Treatment)
Started0021
Completed0013
Not completed008
Withdrew: Adverse event002
Withdrew: Lack of efficacy003
Withdrew: Withdrawal by subject003

Outcome measures

PrimaryPercentage of Participants With at Least 2-step Reduction in Vitreous Haze (VH) or Prednisone Dose <10 mg/Day at Week 16

At least 2-step reduction in VH per central review from baseline was evaluated on Miami 9-step scale. VH is the obscuration of fundus by vitreous cells and protein exudation. Each of the 9-step scale (from grade 0 \[low opacity\] to 8 \[more opacity\]) images (in increasing order of opacity) are equivalent to approximately 0.3 log units of degradation in visual acuity based on the Bangerter calibration. Participants with prednisone dose \<10 mg/day (or equivalent oral corticosteroid) were also evaluated.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least 2-step Reduction in Vitreous Haze (VH) or Prednisone Dose <10 mg/Day at Week 16
Percentage of participantsPlacebo (Part A)Sarilumab 200 mg q2w (Part A)
Percentage of Participants With at Least 2-step Reduction in Vitreous Haze (VH) or Prednisone Dose <10 mg/Day at Week 1630.046.1
Statistical analysis
  • Placebo (Part A) vs Sarilumab 200 mg q2w (Part A) · Cochran-Mantel-Haenszel · p = 0.2354 (Threshold for significance at 0.05 level.) · Odds ratio (or): 2.1 · 90% CI 0.8 to 5.6Sarilumab 200 mg q2w vs Placebo
SecondaryChange From Baseline in VH Scale at Week 16

Change from baseline in VH scale was evaluated on Miami 9-step scale. VH is the obscuration of fundus by vitreous cells and protein exudation. Each of the 9-step scale (from grade 0 \[low opacity\] to 8 \[more opacity\]) images (in increasing order of opacity) were equivalent to approximately 0.3 log units of degradation in visual acuity based on the Bangerter calibration. Least squares (LS) mean was calculated using mixed model for repeated measurements (MMRM) model with treatment groups, visits and visit-by-treatment groups interaction as fixed categorical effects as well as fixed continuous covariate of baseline adjudicated VH.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in VH Scale at Week 16
units on a scalePlacebo (Part A)Sarilumab 200 mg q2w (Part A)
Change From Baseline in VH Scale at Week 16-0.1 ± 0.23-0.9 ± 0.16
Statistical analysis
  • Placebo (Part A) vs Sarilumab 200 mg q2w (Part A) · Mixed Models Analysis · p = 0.0127 (Threshold for significance at 0.05 level.) · Least square (ls) mean difference: -0.7 · 90% CI -1.223 to -0.262Sarilumab 200 mg q2w vs Placebo
SecondaryPercentage of Participants With Anterior Chamber (AC) Cell Score = 0 or At Least 2-step Reduction in Score at Week 16

Participants with AC cell score = 0 or with ≥2 step reduction from baseline at Week 16 were evaluated. Slit lamp examinations were conducted at each visit to assess AC cell count. The number of AC cells observed within a 1 mm × 1 mm slit beam was used to determine the grade according to the Standardization of Uveitis Nomenclature (SUN) criteria: grade 0 = no cells; grade +0.5 = 1 - 5 cells; grade +1 = 6 - 25 cells; grade +2= 26 - 50 cells; grade +3 = too many to count.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With Anterior Chamber (AC) Cell Score = 0 or At Least 2-step Reduction in Score at Week 16
Percentage of participantsPlacebo (Part A)Sarilumab 200 mg q2w (Part A)
Percentage of Participants With Anterior Chamber (AC) Cell Score = 0 or At Least 2-step Reduction in Score at Week 1686.786.2
Statistical analysis
  • Placebo (Part A) vs Sarilumab 200 mg q2w (Part A) · Cochran-Mantel-Haenszel · p = 1 (Threshold for significance at 0.05 level.) · Odds ratio (or): 0.95 · 90% CI 0.11 to 6.093Sarilumab 200 mg q2w vs Placebo
SecondaryChange From Baseline in Best Corrected Visual Acuity (BCVA) Score at Week 16

BCVA score is based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters, and then at 1 meter. The range of ETDRS is 0 to 100 letters. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. LS mean was calculated using MMRM model with treatment groups, randomization strata of VH level (\<4, \>=4), visits and visit-by-treatment groups interaction as fixed categorical effects, as well as, fixed continuous covariate of baseline BCVA.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at Week 16
units on a scalePlacebo (Part A)Sarilumab 200 mg q2w (Part A)
Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at Week 163.5 ± 1.849.3 ± 1.36
Statistical analysis
  • Placebo (Part A) vs Sarilumab 200 mg q2w (Part A) · Mixed Models Analysis · p = 0.0153 (Threshold for significance at 0.05 level.) · Ls mean difference: 5.8 · 90% CI 1.99 to 9.67Sarilumab 200 mg q2w vs Placebo
SecondaryChange From Baseline in Central Retinal Thickness (CRT) At Week 16

CRT was measured by spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. All images were transmitted to the central reading center. SD-OCT was performed in the study eye after pupil dilation. LS mean was calculated using MMRM model with treatment groups, randomization strata of VH level (\<4, \>=4), visits and visit-by-treatment groups interaction as fixed categorical effects, as well as, fixed continuous covariate of baseline CRT.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · µm (microns)
Change From Baseline in Central Retinal Thickness (CRT) At Week 16
µm (microns)Placebo (Part A)Sarilumab 200 mg q2w (Part A)
Change From Baseline in Central Retinal Thickness (CRT) At Week 16-8.9 ± 11.46-35.4 ± 8.36
Statistical analysis
  • Placebo (Part A) vs Sarilumab 200 mg q2w (Part A) · Mixed Models Analysis · p = 0.0683 (Threshold for significance at 0.05 level.) · Ls mean difference: -26.5 · 90% CI -50.41 to -2.68Sarilumab 200 mg q2w vs Placebo
SecondaryPercent Change From Baseline in CRT at Week 16

CRT was measured by SD-OCT, a non-invasive diagnostic system providing high-resolution imaging sections of the retina. All images were transmitted to the central reading center. SD-OCT was performed in the study eye after pupil dilation. LS mean was calculated using MMRM model with treatment groups, randomization strata of VH level (\<4, \>=4), visits and visit-by-treatment groups interaction as fixed categorical effects, as well as, fixed continuous covariate of baseline CRT.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline in CRT at Week 16
percent changePlacebo (Part A)Sarilumab 200 mg q2w (Part A)
Percent Change From Baseline in CRT at Week 160.0 ± 2.90-6.4 ± 2.15
Statistical analysis
  • Placebo (Part A) vs Sarilumab 200 mg q2w (Part A) · Mixed Models Analysis · p = 0.0825 (Threshold for significance at 0.05 level.) · Ls mean difference: -6.4 · 90% CI -12.374 to -0.35Sarilumab 200 mg q2w vs Placebo
SecondaryPercentage of Participants With CRT Thickness <300 Microns at Week 16
Time frame:
Week 16

No measurements were reported for this outcome.

SecondaryPercentage of Participants Without Retinal Vessel Leakage on Fluorescein Angiography (FA) at Week 16
Time frame:
Week 16

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Prednisone Dose of ≤5 mg/Day (or Equivalent Oral Corticosteroid) at Week 16

Participants with prednisone dose ≤5 mg/day (or equivalent oral corticosteroid) at Week 16 were evaluated.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With Prednisone Dose of ≤5 mg/Day (or Equivalent Oral Corticosteroid) at Week 16
Percentage of participantsPlacebo (Part A)Sarilumab 200 mg q2w (Part A)
Percentage of Participants With Prednisone Dose of ≤5 mg/Day (or Equivalent Oral Corticosteroid) at Week 1640.041.4
Statistical analysis
  • Placebo (Part A) vs Sarilumab 200 mg q2w (Part A) · Cochran-Mantel-Haenszel · p = 1 (Threshold for significance at 0.05 level.) · Odds ratio (or): 1.07 · 90% CI 0.306 to 3.845Sarilumab 200 mg q2w vs Placebo
SecondaryPharmacokinetics (PK) Assessment: Serum Functional Sarilumab Concentration

Serum functional (unbound) sarilumab concentrations were determined using an enzyme-linked immunosorbent assay (ELISA) method with a lower limit of quantification (LLOQ) of 294 ng/mL. Concentrations below LLOQ were set to zero for samples at predose. Post-treatment concentrations below LLOQ were replaced by LLOQ/2. The samples were considered non-eligible for the analysis if the previous dosing time was \<11 days or \>17 days before the sampling time for every other week regimens.

Time frame:
Predose on Day 1 (Baseline), Week 2, 4, 8, 12, 16, 24, 36, 52, and end of study (EOS) (Week 56)
Reported as:
Mean · ng/mL
Pharmacokinetics (PK) Assessment: Serum Functional Sarilumab Concentration
ng/mLSarilumab 200 mg q2w (Part A + Part B)
At Baseline0.0 ± 0.0
At Week 27383.3 ± 6547.1
At Week 49876.6 ± 8262.9
At Week 815958.9 ± 12813.1
At Week 1219705.2 ± 15480.9
At Week 1619598.4 ± 17280.8
At Week 2422406.8 ± 14584.2
At Week 3624375.4 ± 19121.7
At Week 5225046.0 ± 17870.7
EOS (Week 56)1730.0 ± NA

Adverse events

Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to the final visit (6 weeks after the last treatment administration [Week 56]) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Part A + Part B)—2/20 (10%)13/20 (65%)
Sarilumab 200 mg q2w (Part A+ Part B)—5/38 (13.2%)25/38 (65.8%)
Sarilumab 200 mg q2w: Open-Label Treatment (Part C)—0/21 (0%)15/21 (71.4%)
Most frequent serious events
Most frequent serious events
EventPlacebo (Part A + Part B)Sarilumab 200 mg q2w (Part A+ Part B)Sarilumab 200 mg q2w: Open-Label Treatment (Part C)
Abortion inducedSurgical and medical procedures0/202/380/21
Staphylococcal sepsisInfections and infestations1/200/380/21
Intraocular pressure increasedInvestigations1/200/380/21
HypoaesthesiaNervous system disorders1/200/380/21
Deep vein thrombosisVascular disorders1/200/380/21
NeutropeniaBlood and lymphatic system disorders0/201/380/21
UveitisEye disorders0/201/380/21
Liver function test increasedInvestigations0/201/380/21
Most frequent other events
Showing 10 of 31
Most frequent other events
EventPlacebo (Part A + Part B)Sarilumab 200 mg q2w (Part A+ Part B)Sarilumab 200 mg q2w: Open-Label Treatment (Part C)
NasopharyngitisInfections and infestations1/202/386/21
Accidental overdoseInjury, poisoning and procedural complications4/203/381/21
UveitisEye disorders2/206/381/21
CoughRespiratory, thoracic and mediastinal disorders3/204/380/21
DiarrhoeaGastrointestinal disorders0/201/383/21
Behcet's syndromeVascular disorders1/201/383/21
NeutropeniaBlood and lymphatic system disorders0/204/381/21
InfluenzaInfections and infestations0/204/382/21
HeadacheNervous system disorders2/204/382/21
PyrexiaGeneral disorders2/200/380/21

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboSarilumab 200 mg q2wTotal
Mean41.5 ± 13.039.3 ± 15.340.0 ± 14.5
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboSarilumab 200 mg q2wTotal
Female132336
Male71522
08

Study locations

20 sites
  • Investigational Site Number 840008
    Worcester, Massachusetts 01608, United States
  • Investigational Site Number 840009
    Omaha, Nebraska 68198-5540, United States
  • Investigational Site Number 840005
    Slingerlands, New York 12159, United States
  • Investigational Site Number 840007
    Cleveland, Ohio 44195, United States
  • Investigational Site Number 840006
    Arlington, Texas 76012, United States
  • Investigational Site Number 203001
    Brno, 62500, Czechia
  • Investigational Site Number 203002
    Praha 2, 12808, Czechia
  • Investigational Site Number 250001
    Paris, 75013, France
  • Investigational Site Number 250002
    Paris, 75571, France
  • Investigational Site Number 380001
    Milano, 20132, Italy
  • Investigational Site Number 380003
    Padova, 35128, Italy
  • Investigational Site Number 380004
    Reggio Emilia, 42100, Italy
  • Investigational Site Number 724003
    Barcelona, 08028, Spain
  • Investigational Site Number 724001
    Barcelona, 08907, Spain
  • Investigational Site Number 792001
    Ankara, 06100, Turkey
  • Investigational Site Number 792005
    Ankara, 06100, Turkey
  • Investigational Site Number 792002
    Istanbul, 34093, Turkey
  • Investigational Site Number 792003
    Istanbul, 34098, Turkey
  • Investigational Site Number 792004
    Izmir, 35100, Turkey
  • Investigational Site Number 792006
    Izmir, 35100, Turkey
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Jul 2015 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2017, 1 year 11 months after primary completion. A results delay was requested in Mar 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2013
First posted
Jul 16, 2013
Start
Oct 2013
Primary completionActual
Jul 2015
CompletionActual
Apr 2016
Results delay requested
Mar 7, 2016
Results first posted
Jun 20, 2017
Last update
Jun 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01900431
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jul 16, 2013
Start date
Oct 2013
Primary completion
Jul 2015
Completion
Apr 2016
Results posted
Jun 20, 2017
Last update
Jun 20, 2017

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sarilumab

Start the discussion